undamentalytics Newsletter
Sign in

Arrowhead Pharmaceuticals, Inc. income statement

In fiscal 2025, Arrowhead Pharmaceuticals, Inc. reported revenue of $829m, up 23258.2% on the year before, operating income of $98.3m (a 11.9% margin) and net income of −$1.6m, or −$0.01 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Revenue0000003116169881382432414829669
Research and development359234762515381129206297353506607723
General and administrative463682417192752811249399124—
Operating income−10−21−25−53−96−82−37−5661−93−149−179−205−60198−226
Interest expense——————————0018328993
Net interest income00−01————————————
Income before tax−9−22−32−59−92−82−34−5468−85−141−173−206−61252−252
Income tax———0000000043−32120
Net income−3−21−31−59−92−82−34−5468−85−141−176−205−599−2−320
Diluted EPS−$0.20−$0.95−$0.65−$1.25−$1.60−$1.34−$0.47−$0.65$0.69−$0.84−$1.36−$1.67−$1.92−$5.00−$0.01−$2.27
Diluted shares (average)16m22m48m47m57m61m74m84m99m101m104m105m107m120m134m141m
EBITDA−10−19−23−52−94−78−34−5364−89−142−170−194−584121−202

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARWR vs NRIXARWR vs RAREARWR vs MIRMARWR vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arrowhead Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arrowhead Pharmaceuticals, Inc.